Approval · Notice of Compliance 35835 · 2025
OZEMPIC: Notice of Compliance 35835
Issued August 13, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 35835
- Date
- August 13, 2025
- Company
- Novo Nordisk Canada IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- OZEMPIC is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| OZEMPIC | Not yet assigned | — |
Medicinal ingredients
- SEMAGLUTIDE 1.34 MG per ML
- SEMAGLUTIDE 2.68 MG per ML
- SEMAGLUTIDE 0.68 MG per ML